Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7210789 | 0.76 | SIGMAR1 (0.35) | ALOX15SIGMAR1STSCYP19A1HSD17B1 | |
| SCHEMBL5846259 | 0.76 | RXRA (0.46) | SIGMAR1 | |
| SCHEMBL4711277 | 0.74 | BCHE (0.38) | — | |
| SCHEMBL29705959 | 0.73 | ALOX15 (0.34) | ALOX15 | |
| SCHEMBL20209377 | 0.73 | ALOX15 (0.34) | ALOX15 | |
| SCHEMBL4460389 | 0.71 | RXRA (0.33) | ALOX15SIGMAR1 | |
| SCHEMBL13770024 | 0.69 | — | — | |
| SCHEMBL48448 | 0.68 | ALOX15 (0.53) | ALOX15 | |
| SCHEMBL1496260 | 0.66 | CYP19A1 (0.39) | SIGMAR1STSCYP19A1HSD17B1 | |
| SCHEMBL4233044 | 0.66 | SIGMAR1 (0.37) | SIGMAR1STSCYP19A1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534544-B1 | Administering retinoid compound as anticarcinogenic and antitumor agents; side effect reduction | ALLERGAN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | ALLERGAN SALES, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6342602-B1 | BIND SPECIFICALLY OR SELECTIVELY TO RAR-ALPHA RECEPTORS | ALLERGAN SALES, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-0876330-B1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6124455-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6034244-A | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTICANCER AGENT | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5856490-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN (US) | 1999-01-05 | — | — | US | disclosed |
| US-5675024-A | RETINOID RECEPTOR AGONISTS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | RARG, RARA, RARB | ALOX15 850/4885SIGMAR1 2813/4885STS 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.